GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TaiGen Biopharmaceuticals Holdings Ltd (ROCO:4157) » Definitions » Gross Margin %

TaiGen Biopharmaceuticals Holdings (ROCO:4157) Gross Margin % : 54.36% (As of Sep. 2024)


View and export this data going back to 2013. Start your Free Trial

What is TaiGen Biopharmaceuticals Holdings Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. TaiGen Biopharmaceuticals Holdings's Gross Profit for the three months ended in Sep. 2024 was NT$4.7 Mil. TaiGen Biopharmaceuticals Holdings's Revenue for the three months ended in Sep. 2024 was NT$8.6 Mil. Therefore, TaiGen Biopharmaceuticals Holdings's Gross Margin % for the quarter that ended in Sep. 2024 was 54.36%.


The historical rank and industry rank for TaiGen Biopharmaceuticals Holdings's Gross Margin % or its related term are showing as below:

ROCO:4157' s Gross Margin % Range Over the Past 10 Years
Min: 62.57   Med: 88.72   Max: 99.02
Current: 90.72


During the past 13 years, the highest Gross Margin % of TaiGen Biopharmaceuticals Holdings was 99.02%. The lowest was 62.57%. And the median was 88.72%.

ROCO:4157's Gross Margin % is ranked better than
87.01% of 747 companies
in the Biotechnology industry
Industry Median: 60.58 vs ROCO:4157: 90.72

TaiGen Biopharmaceuticals Holdings had a gross margin of 54.36% for the quarter that ended in Sep. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for TaiGen Biopharmaceuticals Holdings was 4.10% per year.


TaiGen Biopharmaceuticals Holdings Gross Margin % Historical Data

The historical data trend for TaiGen Biopharmaceuticals Holdings's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TaiGen Biopharmaceuticals Holdings Gross Margin % Chart

TaiGen Biopharmaceuticals Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 62.57 82.77 99.02 89.69 90.70

TaiGen Biopharmaceuticals Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 61.85 76.29 63.01 96.61 54.36

Competitive Comparison of TaiGen Biopharmaceuticals Holdings's Gross Margin %

For the Biotechnology subindustry, TaiGen Biopharmaceuticals Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TaiGen Biopharmaceuticals Holdings's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TaiGen Biopharmaceuticals Holdings's Gross Margin % distribution charts can be found below:

* The bar in red indicates where TaiGen Biopharmaceuticals Holdings's Gross Margin % falls into.



TaiGen Biopharmaceuticals Holdings Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

TaiGen Biopharmaceuticals Holdings's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=111.7 / 123.134
=(Revenue - Cost of Goods Sold) / Revenue
=(123.134 - 11.448) / 123.134
=90.70 %

TaiGen Biopharmaceuticals Holdings's Gross Margin for the quarter that ended in Sep. 2024 is calculated as


Gross Margin % (Q: Sep. 2024 )=Gross Profit (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=4.7 / 8.611
=(Revenue - Cost of Goods Sold) / Revenue
=(8.611 - 3.93) / 8.611
=54.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


TaiGen Biopharmaceuticals Holdings  (ROCO:4157) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

TaiGen Biopharmaceuticals Holdings had a gross margin of 54.36% for the quarter that ended in Sep. 2024 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


TaiGen Biopharmaceuticals Holdings Gross Margin % Related Terms

Thank you for viewing the detailed overview of TaiGen Biopharmaceuticals Holdings's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


TaiGen Biopharmaceuticals Holdings Business Description

Traded in Other Exchanges
N/A
Address
No. 138 Xinming Road, 7th Floor, Neihu District, Taipei, TWN, 114
TaiGen Biopharmaceuticals Holdings Ltd is mainly engaged in the research and development of new drugs, including the selection of drug candidates, pre-IND trials and clinical trials. Its operating segment includes development, research and sales of new drugs, and other.

TaiGen Biopharmaceuticals Holdings Headlines

No Headlines